Skip to main content

Web Exclusives

Breast Cancer

Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer

Immunotherapy

Immunotherapy Combinations “Raising the Bar”

Screening

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

Breast Cancer

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

Immunotherapy, Multiple Myeloma

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation

FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines

Eileen Koutnik-Fotopoulos

Immunotherapy

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

Immunotherapy

CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells

FDA Updates

A Dynamic FDA Has Led to More Rapid Cancer Drug Development

Page 28 of 43
Results 271 - 280 of 425